Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAPY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Adaptimmune Therapeutics Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Adaptimmune Therapeutics Plc's regulatory disclosures and financial reporting.
Adaptimmune Therapeutics plc received a Schedule 13G from Long Focus Capital Management, LLC and John Helmers regarding its American Depositary Shares, each representing 6 ordinary shares. As of the close of business on December 31, 2025, the filing reports beneficial ownership of 0 ADS, representing 0% of the class, with no sole or shared voting or dispositive power.
The securities referenced were purchased in client accounts managed by Long Focus, and no individual client owns more than 5% of the class. The filers certify the holdings are in the ordinary course of business and not for influencing control of Adaptimmune.